Effects of Primary Physician Presence in AI-Synthesized SGLT2 Inhibitor Educational Videos for Heart Failure
Key facts
- Who runs it
- Keimyung University Dongsan Medical Center
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 150 people, planned
- Started
- 21 Aug 2026
- Expected to end
- 31 Jul 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- SGLT2 Inhibitor Educational Video
- Record updated
- 16 November 2026
Who can take part
- Age
- 19 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Adults aged 19 years or older
- Patients diagnosed with heart failure or those visiting the cardiology outpatient clinic with suspected heart failure symptoms (e.g., dyspnea, edema)
- Patients currently taking or scheduled to be prescribed SGLT2 inhibitors for the treatment of heart failure
- Patients who are able to watch the educational video during the outpatient waiting time and complete the survey after the consultation
- Patients who fully understand the purpose and procedures of this study and voluntarily provide written informed consent
Who cannot take part
- Patients with expected acute exacerbation of heart failure or a life expectancy of 1 year or less
- Patients scheduled for heart failure-related surgery or procedures
- Patients who are currently participating in, or have participated in within the past 6 months, another intervention study related to heart failure education
- Patients who do not understand the contents of this study or do not consent to the study due to cognitive decline, etc
- Patients who have difficulty watching the video due to visual or hearing impairments
- Other patients deemed inappropriate for study participation by the investigator
This trial is currently available in South Korea.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the effect of the primary attending physician's presence in educational videos on patient satisfaction and educational effectiveness.
The 4 groups in the trial
- Doctor A - Attending Physician VideoTreatment being tested
Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as their primary physician.
Treatment: SGLT2 Inhibitor Educational Video
- Doctor A - Non-Attending Physician VideoExisting treatment, for comparison
Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor A is presented as a general cardiologist (non-attending).
Treatment: SGLT2 Inhibitor Educational Video
- Doctor B - Attending Physician VideoTreatment being tested
Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as their primary physician.
Treatment: SGLT2 Inhibitor Educational Video
- Doctor B - Non-Attending Physician VideoExisting treatment, for comparison
Participants watch an AI-generated educational video during outpatient waiting time, in which Doctor B is presented as a general cardiologist (non-attending).
Treatment: SGLT2 Inhibitor Educational Video
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of Primary Physician Presence in SGLT2 Inhibitor-Focused Heart Failure Educational Videos During Outpatient Waiting Time on Patient Satisfaction and Educational Effectiveness : A Randomized 2x2 Factorial Study
- Record updated
- 16 November 2026